Tki - OmicsDI

Show results for

Unknown (3811)
Genomics (498)
Transcriptomics (372)
Proteomics (81)
Clinical (16)
Other (14)
Methylation profiling (6)
Models (4)
Multiomics (1)

Organisms

Homo sapiens (416)
Mus musculus (74)
Acidithiobacillus ferrooxidans ATCC 53993 (64)
Aerococcus urinae NBRC 15544 = CCUG 36881 (64)
Allexis (64)
Arabidopsis thaliana (64)
Candida albicans (64)
Cyanophora paradoxa (64)
Ensifer adhaerens (64)
Enterococcus faecalis (64)
Globicatella sanguinis (64)
Histomonas meleagridis (64)
Rattus norvegicus (4)
cellular organisms (2)
Canis lupus familiaris (2)
Fusarium sinicum (2)
Saccharomyces cerevisiae (1)
Betapolyomavirus macacae (1)
Human betaherpesvirus 6B (1)
human gammaherpesvirus 4 (1)
JC polyomavirus (1)
Herpesvirus saimiri (strain 11) (1)
Merkel cell polyomavirus (1)
Macacine alphaherpesvirus 1 (1)
Betapolyomavirus hominis (1)
Human alphaherpesvirus 2 (1)
Human alphaherpesvirus 1 (1)
Human gammaherpesvirus 8 (1)
Human immunodeficiency virus 1 (1)
Human betaherpesvirus 5 (1)

Organisms

Homo sapiens (288)
Mus musculus (51)
human gut metagenome (2)
Canis lupus familiaris (1)
Rattus norvegicus (1)

Repository

ENA (410)
geo (305)
biostudies-arrayexpress (127)
pride (64)
EGA (41)
jPOST (7)
iProX (5)
BioModels (4)
EVA (4)
LINCS (4)
MassIVE (3)
GPMDB (2)
PAXDB (1)

Tissue

Cell culture (17)
Epithelial cell (10)
Lung (9)
Lung epithelium (6)
Permanent cell line cell (6)
Blood (5)
Blood cell (3)
Bone marrow (3)
Brain (3)
Colon (2)
Liver (2)
Stem cell (2)
Type II pneumocyte (2)
Astrocyte (1)
B cell (1)
Blood plasma (1)
C2C12 cell (1)
Cell suspension culture (1)
Fibroblast (1)
Heart (1)
Hepatocyte (1)
Kidney (1)
Leukocyte (1)
Macrophage (1)
Myeloid cell (1)
Neuroblastoma cell (1)
Peripheral blood mononuclear cell (1)
Renal principal cell (1)
Skeletal muscle myoblast (1)

Disease

Lung cancer (9)
Non-small cell lung carcinoma (8)
Lung adenocarcinoma (7)
Colorectal Neoplasms (6)
Chronic myeloid leukemia (5)
Acute leukemia (4)
Gastrointestinal Stromal Tumors (2)
Neoplasms (2)
Not Available (2)
Acute myeloid leukemia (2)
Colon cancer (2)
Neuroblastoma (2)
Hodgkins lymphoma (1)
Normal (1)
Colon cancer metastatic (1)
Hepatocellular carcinoma (1)
Melanoma (1)
Stomach Neoplasms (1)
Colorectal cancer (1)
Colorectal Cancer (1)
Brain glioblastoma multiforme (1)
Cachexia (1)
Chronic bronchitis (1)
Glioblastoma (1)
Lung carcinoma (1)
Renal cell carcinoma (1)
Rhabdoid cancer (1)
Squamous cell carcinoma (1)

Technology Type

Mass Spectrometry (64)
Shotgun proteomics (34)
Bottom-up proteomics (14)
Data-dependent acquisition (8)
Affinity purification coupled with mass spectrometry proteomics (7)
Data-independent acquisition (3)
Illumina HiSeq 2000 (2)
Fluorescence intensity (2)
MSE (2)
SRM/MRM (2)
Top-down proteomics (2)
Illumina HiSeq 2500, Illumina HiSeq 2000 (ILLUMINA), Illumina HiSeq 2000, Illumina (1)
Infinium_OmniExpress-24v1.0 (1)
ILLUMINA, NextSeq 500 (1)
AB 5500 Genetic Analyzer (1)
HiSeq X Ten, Illumina HiSeq 2500, ILLUMINA (1)
DNA sequencing (1)
KINOMEscan (1)
PCR (1)
RNA-seq (1)
Affinity proteomics (1)
DiaPASEF (1)
Gel-based experiment (1)

Instrument Platform

Illumina NovaSeq 6000 (3)
Ion Torrent PGM (2)
Instrument (2)
Q Exactive (2)
ABI SOLiD v4 (1)
HiSeq X Five (1)
AB SOLiD 4 System (1)
Illumina Genome Analyzer IIx (1)
Illumina HiSeq 2500 (1)
Illumina HiSeq 4000 (1)
NextSeq 500 (1)
Illumina (1)
Unspecified (1)
LTQ Orbitrap Elite (1)
Q Exactive HF-X (1)

Publication Date

2025 (69)
2026 (52)
2024 (43)
2023 (42)
2016 (37)
2020 (33)
2022 (33)
2015 (30)
2021 (25)
2019 (22)
2018 (21)
2012 (18)
2017 (17)
2014 (15)
2013 (15)
2011 (15)
2010 (14)
2009 (11)
2008 (5)
2007 (4)
2005 (2)
2006 (1)

UNIPROT ID/AC

Q9Y6I3 (2)
O14781 (2)
Q15466 (2)
P22681 (2)
Q8NEB9 (2)
O15357 (2)
O00459 (2)
Q13115 (2)
P40763 (2)
P31751 (2)
P28562 (2)
P01112 (2)
P01133 (2)
P00533 (2)
P60484 (2)
O15530 (2)
Q16828 (2)
P04049 (2)
Q02750 (2)
P28482 (2)
Q07889 (2)
P98077 (2)
P20936 (2)
P62993 (2)
P51452 (1)
1433B_HUMAN (1)
1433E_HUMAN (1)
1433F_HUMAN (1)
1433G_HUMAN (1)
1433S_HUMAN (1)

CHEBI ID

CHEBI:16541 (2)
CHEBI:15996 (2)
CHEBI:17552 (2)
CHEBI:37328 (1)
CHEBI:33699 (1)

First Public Date

2025 (66)
2026 (53)
2024 (53)
2023 (45)
2022 (33)
2020 (31)
2021 (28)
2014 (21)
2017 (20)
2019 (18)
2015 (15)
2016 (14)
2018 (11)
2013 (2)

Modelling Approach

Ordinary differential equation model (3)

Study status

Recruiting (6)
Not yet recruiting (3)
Completed (3)
Terminated (2)
Suspended (1)
Not provided (1)

Lab affiliation

Moffitt Cancer Center Tampa, FL, USA (6)
OncoProteomics Laboratory, Dept of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands (4)
Amsterdam UMC, Vrije Universiteit Amsterdam, Medical Oncology, Cancer Center Amsterdam, OncoProteomics Laboratory, Amsterdam, Netherlands (3)
Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA (2)
Drug Discovery Moffitt Cancer Center Tampa, FL, USA (2)
Assistant Research Specialist, Institute of Chemistry, Academia Sinica (1)
Associate Professor Director of Graduate Studies BMBB Biochemistry, Molecular Biology, and Biophysics 7-140 MCB 420 Washington Avenue SE Minneapolis, MN 55455 (1)
Biomolecular Mass Spectrometry and Proteomics Bijvoet Center for Biomolecular Research Utrecht University (1)
Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, the Netherlands. Netherlands Proteomics Centre, Padualaan 8, 3584 CH Utrecht, the Netherlands (1)
Center for Thoracic Cancers, MGH Cancer Center Massachusetts General Hospital Harvard Medical School USA (1)
Centre for Clinical Proteomics, Odense University Hospital, Sdr Boulevard 29, DK-5000 Odense C (1)
City of Hope Beckman Research Institute (1)
Core Facility Proteomics Hannover Medical School Carl-Neuberg-Str. 1 30625 Hannover Germany (1)
Debora Bonenfant, Novartis Institutes for Biomedical research, Basel, Switzerland (1)
Department of Biochemistry & Biomedicine, School of Life Sciences, University of Sussex (1)
Department of Biochemistry, Western University (1)
Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. (1)
Department of Clinical Pathology, First Affiliated Hospital of Jinan University, Guangzhou, China (1)
Department of Functional Genomics, Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany (1)
Department of Hematology and Oncology, University of Tübingen, Germany (1)
Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China (1)
Department of Medical Biochemistry and Cell Biology, Instititute of Biomedicine at the Sahlgrenska Academy, University of Gothenburg, Sweden. (1)
Dept. Oncology Pathology, Karolinska Institutet, Scilifelab, Stockholm, Sweden (1)
Dept. of Bioloy, University of Rome Tor Vergata (1)
Dept. of Radiation Oncology, The University of Michigan Medical School, Medical Science Building I, Ann Arbor, MI 48109 (1)
INSERM U1016, Institut Cochin, CNRS UMR8104, Paris, France; Université Paris Descartes, Faculté de Médecine Sorbonne Paris Cité, Paris, France; Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France. (1)
Imperial College London (1)
Institute for Diabetes and Obesity, Helmholtz Zentrum München, 85764 Neuherberg, Germany German Center for Diabetes Research, Neuherberg, Germany (1)
Institute of Bioinformatics, Bangalore, Karnataka, India (1)
Institute of Biological Chemistry, Academia Sinica (1)

Keyword

Bevacizumab (3)
Apatinib (2)
Colorectal cancer, cetuximab, biomarker, prometheus (1)
NTRK (1)
Carcinoma, NSCL (1)
Non Small Cell Lung (1)
Thyroid Disease (1)
Thyroid Neoplasms (1)
Carcinoma, Neuroendocrine (1)
Respiratory Tract Neoplasms (1)
Lung Disease (1)
Respiratory Tract Disease (1)
Carcinoma, Bronchogenic (1)
Bronchial Neoplasms (1)
Endocrine System Disease (1)
Colorectol Neoplasms (1)
Colonic Disease (1)
Intestinal Disease (1)
Endocrine Gland Neoplasms (1)
Non Small Cell Lung Cancer (1)
Rearrangements (1)
TRIDENT-1 (1)
TKI (1)
TKI naive (1)
TKI pretreated (1)
Anti-tumor activity (1)
Repotrectinib (1)
Advanced Solid Malignancies (1)
Gastrointestinal Microbiome (1)
Gastrointestinal Disease (1)

IsPrivate

False (4)

Study type

Transcription profiling by array (93)
RNA-seq of coding RNA (12)
Interventional (12)
Comparative genomic hybridization by array (4)
Observational (4)
MicroRNA profiling by array (3)
DNA-seq (3)
Genotyping by array (2)
RNA-seq of coding RNA from single cells (2)
ChIP-chip by tiling array (1)
One-color microarray (1)
Human - High-throughput sequencing (1)
Cell line - One-color microarray (1)
Transcription profiling by RT-PCR (1)
ChIP-seq (1)
Methylation profiling by array (1)
RNA-seq of non coding RNA (1)

Release Date

2022 (527)
2023 (482)
2021 (461)
2025 (385)
2024 (365)
2020 (357)
2019 (271)
2018 (247)
2016 (198)
2017 (157)
2015 (116)
2014 (89)
2013 (79)
2026 (68)
2011 (41)
2012 (35)
2010 (23)
2009 (19)
2008 (9)
2007 (5)
2006 (2)
2005 (1)

Location

China (8)
France (3)
Singapore (2)
South Korea (2)
Italy (2)
Netherlands (2)
United States (2)
Hong Kong (1)
Taiwan (1)
North Korea (1)
Denmark (1)
Poland (1)
Germany (1)
Spain (1)
Belgium (1)
Hungary (1)
Canada (1)
Australia (1)
United Kingdom (1)
Japan (1)

Previous page
1 / 481
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 481
Next page

Sort by:

Relevance

Page size

TKI

PRJEB37289 | ENA

Gene expression changes during resistance toward vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) therapy in renal cell carcinoma (RCC)

This study was performed to understand the gene expression changes that accompany treatment of renal cell carcinoma (RCC) with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) therapy. Human RCC cell lines were implanted into the flanks of nude beige mice, allowed...

ORGANISM(S): Homo sapiens

2015-05-21 | E-GEOD-64052 | biostudies-arrayexpress

Global proteome and phosphoproteome alterations in 3rd generation EGFR TKI resistance reveal drug targets to circumvent resistance

Lung cancer continues to be the leading cause of cancer mortality worldwide. The treatment of lung cancer patients harboring mutant EGFR with orally administered EGFR TKIs has been a paradigm shift. Osimertinib and rociletinib are two 3rd generation irreversible EGFR TKIs targeting the EGFR T790M mu...

ORGANISM(S): Homo sapiens (Human)

2021-03-11 | PXD020108 | Pride

Treatment-free remission and relapse in chronic myeloid leukaemia (CML) patients

Peripheral blood from 70 individuals (31 CML patients who subsequently relapsed after discontinuation of tyrosine kinase inhibitors (TKI) treatment, 29 CML patients who maintained treatment-free remission, and 10 healthy donors) was profiled to investigate transcriptional programs associated with su...

ORGANISM(S): Homo sapiens

2026-06-01 | E-MTAB-16324 | biostudies-arrayexpress

Differential mRNA expression analysis of EGFR-TKI-sensitive cells vs. EGFR-TKI-resistant cells

PRJNA721680 | ENA

Whole exome sequencing of EGFR-TKI naive and EGFR-TKI resistant lung adenocarcinoma samples

PRJEB50602 | ENA

TFF3 drives Hippo dependent EGFR-TKI resistance in lung adenocarcinoma

PRJNA1160153 | ENA

TKI-resistant T790M EGFR Mutation Rewired EGFR Translocation Routes through Switching Interactome in Non-Small Cell Lung Cancer

Epidermal growth factor receptor (EGFR) harboring active mutations, Del19 and L858R, are most common oncogenic mutations in in non-small cell lung cancer (NSCLC) patients. The preferred treatment at first line is tyrosine kinase inhibitor (TKI) administration while the TKI-resistance usually develop...

ORGANISM(S): Homo Sapiens (human)

2023-05-31 | PXD034228 | JPOST Repository

Expression profiling of MET TKI resistant Hs746T cells.

PRJNA1269073 | ENA

Analysis of differentially expressed genes after EGFR-TKI treatment

PRJNA989554 | ENA

Previous page
1 / 481
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 481
Next page

Sort by:

Relevance

Page size

4803 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

UNIPROT ID/AC

CHEBI ID

First Public Date

Modelling Approach

Study status

Lab affiliation

Tags

Keyword

IsPrivate

Study type

Release Date

Location

OmicsDI is part of the ELIXIR infrastructure

Tweets